Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMUX
stocks logo

IMUX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.102
-59.11%
--
--
-0.111
-55.43%
--
--
-0.114
-42.86%
Estimates Revision
The market is revising Downward the revenue expectations for Immunic, Inc. (IMUX) for FY2026, with the revenue forecasts being adjusted by -12.5% over the past three months. During the same period, the stock price has changed by -9.55%.
Revenue Estimates for FY2026
Revise Downward
down Image
-12.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.18%
In Past 3 Month
Stock Price
Go Down
down Image
-9.55%
In Past 3 Month
Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.688
sliders
Low
3.00
Averages
4.25
High
8.00
Current: 0.688
sliders
Low
3.00
Averages
4.25
High
8.00
H.C. Wainwright
Buy
downgrade
$10 -> $8
2025-11-14
Reason
H.C. Wainwright
Price Target
$10 -> $8
2025-11-14
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Immunic to $8 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's share count post the Q3 report.
Roth Capital
Boobalan Pachaiyappan
Buy
initiated
$3
2025-11-07
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$3
2025-11-07
initiated
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic with a Buy rating and $3 price target. The firm says the company has "potential best-in-indication advantages" of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic's Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.
Ladenburg
Aydin Huseynov
initiated
$3
2025-10-16
Reason
Ladenburg
Aydin Huseynov
Price Target
$3
2025-10-16
initiated
Reason
Ladenburg analyst Aydin Huseynov initiated coverage of Immunic with a Buy rating and $3 price target.
Chardan
Rudy Li
Buy
initiated
$13
2025-09-29
Reason
Chardan
Rudy Li
Price Target
$13
2025-09-29
initiated
Buy
Reason
Chardan analyst Rudy Li initiated coverage of Immunic with a Buy rating and $13 price target. The firm cites the potential of the company's lead asset IMU-838 for the treatment of multiple sclerosis for the Buy rating. The drug has a good chance to report positive data from the ongoing Phase 3 studies, the analyst tells investors in a research note.
B. Riley
William Wood
Buy
downgrade
$6 -> $5
2025-05-23
Reason
B. Riley
William Wood
Price Target
$6 -> $5
2025-05-23
downgrade
Buy
Reason
B. Riley analyst William Wood lowered the firm's price target on Immunic to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company's model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic's cash runway well beyond 2026.
B. Riley Securities
William Woods
Strong Buy
Reiterates
$6
2025-04-16
Reason
B. Riley Securities
William Woods
Price Target
$6
2025-04-16
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunic Inc (IMUX.O) is -1.49, compared to its 5-year average forward P/E of -2.04. For a more detailed relative valuation and DCF analysis to assess Immunic Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.04
Current PE
-1.49
Overvalued PE
-0.65
Undervalued PE
-3.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
89.83
Undervalued EV/EBITDA
-68.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1208.68
Current PS
0.00
Overvalued PS
4751.57
Undervalued PS
-2334.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMUX News & Events

Events Timeline

(ET)
2025-11-13
06:33:10
Immunic Announces Q3 Earnings Per Share of 13 Cents, Below Consensus Estimate of 18 Cents
select
2025-09-09 (ET)
2025-09-09
06:44:51
Immunic Granted Notice of Patent Approval for Vidofludimus Calcium
select
2025-08-07 (ET)
2025-08-07
06:46:01
Immunic reports Q2 EPS (20c), consensus (16c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26PRnewswire
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

  • Immunic's Conference Participation: Immunic, Inc. will have its CEO, Daniel Vitt, participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on December 4, 2025, and will also hold one-on-one investor meetings during the event.

  • Lead Development Program: The company's lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, following promising phase 2 results.

  • Additional Drug Development: Immunic is also developing IMU-856, aimed at gastrointestinal diseases, and IMU-381, a next-generation molecule currently in preclinical testing, targeting specific gastrointestinal needs.

  • Forward-Looking Statements Caution: The press release includes cautionary statements regarding forward-looking statements, highlighting risks and uncertainties that could affect the company's future operations and clinical trial outcomes.

[object Object]
Preview
4.0
11-15NASDAQ.COM
HC Wainwright & Co. Upholds Buy Rating for Immunic (IMUX)

  • Analyst Recommendation: HC Wainwright & Co. has maintained a Buy recommendation for Immunic (NasdaqGS:IMUX), with a projected one-year price target of $6.41/share, indicating a potential upside of 718.72% from its current price of $0.78/share.

  • Fund Sentiment: There has been a 15.79% increase in the number of funds reporting positions in Immunic, with total shares owned by institutions rising by 7.50% to 52,173K shares.

  • Shareholder Activity: Notable shareholders include Standard Life Aberdeen and Bvf, with no changes in their holdings, while Tekla Life Sciences Investors significantly increased their stake by 76.60%.

  • Market Outlook: The put/call ratio for IMUX is 0.03, suggesting a bullish sentiment among investors regarding the stock's future performance.

[object Object]
Preview
4.0
11-13Benzinga
D. Boral Capital Reaffirms Buy Rating on Immunic, Reduces Price Target to $8

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immunic Inc (IMUX) stock price today?

The current price of IMUX is 0.6883 USD — it has increased 5.85 % in the last trading day.

arrow icon

What is Immunic Inc (IMUX)'s business?

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

arrow icon

What is the price predicton of IMUX Stock?

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 4.25 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immunic Inc (IMUX)'s revenue for the last quarter?

Immunic Inc revenue for the last quarter amounts to -25.99M USD, increased 1.04 % YoY.

arrow icon

What is Immunic Inc (IMUX)'s earnings per share (EPS) for the last quarter?

Immunic Inc. EPS for the last quarter amounts to -20207000.00 USD, decreased -3.10 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immunic Inc (IMUX)'s fundamentals?

The market is revising Downward the revenue expectations for Immunic, Inc. (IMUX) for FY2026, with the revenue forecasts being adjusted by -12.5% over the past three months. During the same period, the stock price has changed by -9.55%.
arrow icon

How many employees does Immunic Inc (IMUX). have?

Immunic Inc (IMUX) has 91 emplpoyees as of December 05 2025.

arrow icon

What is Immunic Inc (IMUX) market cap?

Today IMUX has the market capitalization of 82.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free